文献速递乳腺癌

风险与密度不同的亚组凸显乳腺癌分层筛查的潜力

Subgroups varying in risk and density highlight the potential for stratified breast cancer screening.
PubMed 文献 · Eur J Cancer · 2025-01-04

研究使用MISCAN微模拟模型模拟荷兰乳腺癌筛查项目在16个按5年乳腺癌风险和乳腺密度划分的亚组中的结局,发现所有结局在风险-密度亚组间存在显著差异,极密乳腺女性当前筛查的死亡率降低为16-17%,其他组为25-29%,假阳性率范围近两倍,终生随访医疗费用差异近九倍,提示分层筛查策略可能改善健康公平并减轻乳腺癌负担。

要点

  • 所有结局在风险-密度亚组间存在显著差异。
  • 极密乳腺女性当前筛查的死亡率降低为16-17%,其他组为25-29%。
  • 假阳性率范围近两倍,终生随访医疗费用差异近九倍。

核心结论

  • 这些发现强调分层筛查策略在改善健康结局公平性和减轻乳腺癌负担方面的潜力。

研究设计与样本

  • 使用MISCAN微模拟模型模拟荷兰筛查项目在16个按5年乳腺癌风险和乳腺密度划分的亚组中的结局。

主要发现

  • 所有结局在风险-密度亚组间存在显著差异。
  • 极密乳腺女性当前筛查的死亡率降低为16-17%,其他组为25-29%。
  • 绝对获益(避免的乳腺癌死亡和获得的生命年)随风险增加,并随密度独立变化。
  • 假阳性率范围在亚组间变化近两倍,终生随访医疗费用差异近九倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most breast cancer screening programs rely only on demographic data without considering individual risk factors of the population, which might limit their effectiveness by over- and underscreening specific subgroups. Therefore, the aim of this study is to highlight health and economic disparities in outcomes from such a uniform screening strategy. With the microsimulation model MISCAN, we simulated outcomes of the Dutch screening program considering 16 subgroups varying by their 5-year breast cancer risk and breast density. All outcomes showed significant disparities across risk-density subgroups. Notably, women with extremely dense breasts showed a mortality reduction from the current screening of 16-17 % compared to 25-29 % in other groups. Absolute benefits (breast cancer deaths averted, and life-years gained) increased with risk and varied independently by density. The range of false-positive rates varied almost twofold across the span of subgroups and nearly a ninefold difference in the medical costs incurred with lifelong follow-up. These findings emphasize the potential for stratified screening strategies to improve equity in health outcomes and reduce the burden of breast cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gil Quessep E, van der Waal D, Peters J, et al. Subgroups varying in risk and density highlight the potential for stratified breast cancer screening. Eur J Cancer. 2025. PMID: 39805236. doi:10.1016/j.ejca.2025.115220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。